000147698 001__ 147698
000147698 005__ 20240229121831.0
000147698 0247_ $$2doi$$a10.1007/s10557-019-06894-w
000147698 0247_ $$2pmid$$apmid:31375970
000147698 0247_ $$2ISSN$$a0920-3206
000147698 0247_ $$2ISSN$$a1573-7241
000147698 0247_ $$2altmetric$$aaltmetric:66574346
000147698 037__ $$aDKFZ-2019-02680
000147698 041__ $$aeng
000147698 082__ $$a610
000147698 1001_ $$0P:(DE-He78)747b703d2a306c4276ea9e4ee9b5fe44$$aHoppe, Liesa$$b0$$eFirst author
000147698 245__ $$aThe Associations of Diuretics and Laxatives Use with Cardiovascular Mortality. An Individual Patient-Data Meta-analysis of Two Large Cohort Studies.
000147698 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2019
000147698 3367_ $$2DRIVER$$aarticle
000147698 3367_ $$2DataCite$$aOutput Types/Journal article
000147698 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579701000_17784
000147698 3367_ $$2BibTeX$$aARTICLE
000147698 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147698 3367_ $$00$$2EndNote$$aJournal Article
000147698 500__ $$a2019 Oct;33(5):567-579
000147698 520__ $$aTo investigate the associations of diuretics overall, non-potassium-sparing diuretics in specific, and laxative use with cardiovascular mortality (CVM) in subjects with antihypertensive treatment.Analyses included 4253 participants, aged 50 to 75 years, from the German ESTHER cohort and 105,359 participants, aged 50 to 69 years, from the UK Biobank. Cox proportional hazard regression models were applied in both studies, and then results were pooled using random-effects model meta-analyses.During 14 and 7 years of follow-up, 476 and 1616 CVM cases were observed in the ESTHER study and the UK Biobank, respectively. Compared to non-users, a 1.6-fold (hazard ratio [95% confidence interval] 1.57 [1.29; 1.90]), a 1.4-fold (1.39 [1.26; 1.53]), and no statistically significantly increased (1.13 [0.94; 1.36]) CVM were observed in users of diuretics overall, non-potassium-sparing diuretics in specific, and laxatives, respectively. Concurrent use of non-potassium-sparing diuretics and laxatives was associated with a 2-fold increased CVM (2.05 [1.55; 2.71]) when compared to users of neither diuretics nor laxatives. However, a test for interaction slightly missed statistical significance (p = 0.075).These consistent results from two large cohort studies imply that more research is needed on the safety of diuretics in routine care. Although not statistically significant in this study, a drug-drug interaction of non-potassium-sparing diuretics and laxatives appears plausible. Physicians and pharmacists are advised to clarify additional laxative use in users of non-potassium-sparing diuretics and inform about the risk of concurrent use. Moreover, closer potassium monitoring intervals (e.g., every 3 months) might be indicated in concurrent users to prevent fatal cardiovascular events.
000147698 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000147698 588__ $$aDataset connected to CrossRef, PubMed,
000147698 7001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aMuhlack, Dana Clarissa$$b1$$udkfz
000147698 7001_ $$aKoenig, Wolfgang$$b2
000147698 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$udkfz
000147698 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b4$$eLast author$$udkfz
000147698 773__ $$0PERI:(DE-600)2003553-6$$a10.1007/s10557-019-06894-w$$n5$$p567-579$$tCardiovascular drugs and therapy$$v33$$x1573-7241$$y2019
000147698 909CO $$ooai:inrepo02.dkfz.de:147698$$pVDB
000147698 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000147698 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000147698 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000147698 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000147698 9141_ $$y2019
000147698 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147698 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147698 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147698 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147698 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCARDIOVASC DRUG THER : 2017
000147698 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147698 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147698 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147698 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147698 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147698 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000147698 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147698 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147698 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000147698 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000147698 980__ $$ajournal
000147698 980__ $$aVDB
000147698 980__ $$aI:(DE-He78)C070-20160331
000147698 980__ $$aI:(DE-He78)C120-20160331
000147698 980__ $$aUNRESTRICTED